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Abstract
The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with reduced risk of 
colorectal neoplasia. Previous studies have reported that polymorphisms in NSAID-metabolizing 
enzymes central to NSAID metabolism including UDP-glucuronosyltransferases (UGT) and 
cytochrome P450 (CYP) 2C9 may modify this protective effect. We investigated whether 35 
functionally relevant polymorphisms within CYP2C9 and UGT genes were associated with 
colorectal cancer risk or modified the protective effect of NSAIDs on colorectal cancer 
susceptibility, using 1,584 colorectal cancer cases and 2,516 unaffected sibling controls from the 
Colon Cancer Family Registry. A three-SNP genotype in UGT1A6 (G-A-A; Ala7-Thr181-Arg184) 
and the Asp85 variant in UGT2B15 increased the risk of colorectal cancer (OR 3.87; 95% CI 
1.04-14.45 and OR 1.34; 95% CI 1.10-1.63, respectively). We observed interactions between 
UGT1A3 Thr78Thr (A>G) and NSAID use (p-interaction=0.02), a three-SNP genotype within 
UGT2B4 and ibuprofen use (p-interaction=0.0018), as well as UGT2B15 Tyr85Asp (T>G) and 
aspirin use (p-interaction=0.01). The interaction with the UGT2B4 and the UGT2B15 
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polymorphisms were noteworthy at the 25% FDR level. This study highlights the need for further 
pharmacogenetic studies to identify individuals who might benefit from NSAID use as part of 
developing effective strategies for prevention of colorectal neoplasia.
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Introduction
Several studies, including randomized trials, have reported protective effects of non-
steroidal anti-inflammatory drugs (NSAIDs) on colorectal carcinogenesis as well as on the 
etiology of other tumors, illustrating the chemopreventive potential of NSAIDs (Flossmann 
and Rothwell, 2007; Cross et al., 2008; Chia et al., 2012; Rothwell et al., 2010; 2012a). 
Many questions remain, however, unanswered, especially regarding dosage, treatment 
duration and long-term benefit of NSAID use (Potter, 2012). NSAIDs reduce inflammation 
through inhibition of prostaglandin synthesis (by blocking prostaglandin-endoperoxide 
synthases 1 (COX-1) and 2 (COX-2)) and thus affect pathways that are relevant for 
carcinogenesis such as proliferation, apoptosis and angiogenesis (Ulrich et al., 2006). In 
support, recent meta-analyses among >24,000 individuals showed a 37% reduction of 
colorectal cancer and a 19% reduction of cancer mortality overall among individuals using 
aspirin (Rothwell et al., 2012a). Interestingly, data on molecular tumor pathology of 
colorectal cancers suggest that the preventive effect of aspirin may be limited to a subset of 
tumors carrying mutations in PI3KCA (Ogino et al., 2013; Tougeron et al., 2013). 
Furthermore, the effectiveness of NSAIDs depends on the bioavailability of the active drug 
compound. Inter-individual differences in drug metabolism may modify therapeutic effects, 
which can be a direct consequence of polymorphisms within related genes (Ulrich et al., 
2006; Cross et al., 2008). Polymorphisms in genes of drug-metabolizing enzymes have long 
been known to have functional impacts on pharmacokinetics, particularly on bioavailability 
(Weber and Hein, 1979; Ciotti et al., 1997; Takahashi et al., 1998). The metabolism of 
NSAIDs primarily involves glycine N-acyltransferase and uridine 5′ diphosphate 
glucuronosyl transferases (e.g. UGT1A6) and cytochrome P450 2C9 (CYP2C9) (Hutt et al., 
1986; Leemann et al., 1993). Thus, interactions between polymorphisms in CYP2C9 or the 
UGT gene families and NSAID use may modify the risk of colorectal cancer.
Previous studies have investigated the effect of selected polymorphisms (CYP2C9*2, 
CYP2C9*3, UGT1A6*2) (Rettie et al., 1994; Haining et al., 1996; Sullivan-Klose et al., 
1996; Ciotti et al., 1997; Steward et al., 1997; Takahashi et al., 1998; Gill et al., 1999; Bigler 
et al., 2001; Chan et al., 2005; Samowitz et al., 2006; Bae et al., 2011) that appear to have 
functional consequences on colorectal cancer risk. Their findings suggest interactions 
between polymorphisms in drug-metabolizing enzymes and NSAID use, highlighting the 
potential of pharmacogenetics to tailor chemoprevention. Variants in UGT genes modified 
the risk of colorectal adenoma dependent on the use of NSAIDs (Bigler et al., 2001; Chan et 
al., 2005). UGT enzymes are phase II drug metabolizing enzymes, which modify xenobiotic 
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or endobiotic compounds through glucuronidation. UGT1A6 variant enzymes were reported 
to display lower activity, resulting in a prolonged exposure to the active drug and 
consequently reduced colorectal adenoma risk (Bigler et al., 2001; Samowitz et al., 2006; 
Chan et al., 2011). However, only little is known about other UGT polymorphisms and their 
interaction with NSAIDs in colorectal cancer susceptibility.
The UGT1A gene family consists of four common exons and at least 13 variable exons, 
resulting in many shared sequences and consequently shared polymorphisms within this 
gene family giving rise to nine functional UGT1A enzymes (Mackenzie et al., 2005). In 
addition, several UGT enzymes share substrate specificity (Kuehl et al., 2005). Therefore, in 
order to study both the effect of UGT1A and UGT2B polymorphisms on risk of colorectal 
cancer and their potential to modify the protective effect of NSAID use on colorectal cancer 
risk, pharmacogenetic investigations of the UGT loci need to be performed in a targeted and 
comprehensive manner. Due to the complex structure of the UGT loci, genetic variation 
within this region is insufficiently covered on standard genome-wide association platforms. 
Consequently, GWAS consortia cannot provide thorough information to improve our 
understanding of the impact of UGT gene polymorphisms on cancer risk and many other 
phenotypes. Thus, many of the UGT variants reported here are being studied for the first 
time for an association with colorectal cancer risk.
We conducted a matched case-sibling control study, based on 1,584 colorectal cancer cases 
and 2,516 healthy controls, investigating a selection of putatively functional single 
nucleotide polymorphisms (SNPs) in ten genes of phase I (CYP2C9) and phase II (UGT) 
drug metabolizing enzymes in relation to risk of colorectal cancer. We also investigated 
combined genotypes across UGT genes, as multiple ‘hits’ in this detoxification machinery 
may be required to have an impact on colorectal carcinogenesis. Finally, a focus of this 




The study population has been described previously (Newcomb et al., 2007). Briefly, 
colorectal cancer cases were recruited for the Colon Cancer Family Registry (CCFR) from 
six registry centers. The CCFR cases were patients and affected relatives diagnosed with 
primary invasive colorectal cancer between 1998 and 2002 who were interviewed within 
five years of diagnosis. Controls were siblings without a colorectal cancer diagnosis at the 
time of enrollment. Although eligibility requirements varied slightly across registry centers, 
participants typically were required to be between the ages of 20 and 74 (Newcomb et al., 
2007). Standard questionnaires were used to collect epidemiologic data from CCFR 
participants regarding demographic characteristics, medical history, NSAID use, family 
history of cancer, smoking history, diet, physical activity, height, and weight. NSAID use 
was defined as regular use in the two years prior to study enrollment. Blood and tissue 
samples were collected according to standardized procedures. Individuals were excluded 
from this study if the case did not have at least one matched unaffected sibling as a control 
or if an individual's sex determined by genotyping did not match reported sex on the 
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questionnaire. Only individuals self-reported as Caucasian and collected through population-
based recruitment, were included in these analyses. Informed consent was obtained from all 
participants. The Institutional Review Boards at each CCFR site approved the study. Blood 
samples were collected according to standardized procedures as described earlier (Newcomb 
et al., 2007) and DNA was extracted from peripheral blood leukocytes and quantified using 
the PicoGreen kit (Invitrogen, Paisley, United Kingdom).
Selection of polymorphisms and genotyping
Polymorphisms were selected based on a candidate gene approach with the aim of assessing 
the association of the complex genetic variation within UGT1A and UGT2B gene families, 
as well as CYP2C9, on both risk and effect modification of NSAID use on colorectal cancer. 
We selected 35 polymorphisms with minor allele frequencies of at least 3% in ten genes to 
capture genetic variants in UGT genes with previously demonstrated functional impact or 
with known amino acid changes (Haining et al., 1996; Ciotti et al., 1997; Takahashi et al., 
1998; Krishnaswamy et al., 2005a; Thomas et al., 2006).
TagSNPs were specifically chosen to capture common non-synonymous variation in the 
UGT1A locus. We used extensive resequencing data from 92 Caucasian individuals 
(Thomas et al., 2006) to determine the LD structure of the locus and identify nsSNPs with 
minor allele frequencies greater than 3%. Outside of the UGT1A locus, the candidate genes 
CYP2C9, UGT2B4, UGT2B7 and UGT2B15 were chosen based on earlier functional work 
supporting their role in NSAID metabolism (Gill et al., 1999; Kuehl et al., 2005; Kuehl et 
al., 2006). With regards to the UGT2B genes, UGT2B4 and UGT2B7 were included because 
of their demonstrated glucuronidation of ibuprofen (Kuehl et al., 2005) and salicylic acid 
(Kuehl et al., 2006). In these experiments, there was little evidence that UGT2B15 or 
UGT2B17 could form acyl and phenolic glucuronides of salicylic acid at detectable levels. 
Furthermore, there were no non-synonymous SNPs in UGT2B17 with minor allele 
frequencies >3%. We included UGT2B15 due to its demonstrated, albeit low, 
glucuronidation of ibuprofen and naproxen in vitro (Kuehl et al., 2006).
TaqMan-based assays were performed for the CYP2C9 polymorphisms R144C (rs1799853) 
and I359L (rs1057910), the UGT1A6 polymorphisms T181A (rs2070959) and R184S 
(rs1105879), the UGT2B4 polymorphism D458E (rs13119049), the UGT2B15 
polymorphism D85Y (rs1902023), and the UGT2B7 polymorphism Y268H (rs7439366) at 
the Fred Hutchinson Cancer Research Center using the Applied Biosystems 7900HT 
Sequence Detection System (Applied Biosystems, Foster City, CA). Genotypes were 
assigned using the Allelic Discrimination Software (Applied Biosystems SDS Software, 
version 2.3). The CYP2C9 and UGT1A6 assays contained 3.75 ng of DNA, 2.5 μl of 2X 
TaqMan Universal PCR Mix (No AmpErase UNG), 300 nmol/L forward primer, 300 
nmol/L reverse primer, 100nmol/L FAM-labeled MGB probe, 100nmol/L VIC-labeled 
MGB probe and double-distilled water to a final volume of 5 μl. Cycling conditions were 
50°C 2min, 95°C 10min, 40 × 95°C, 15sec; 60°C, 1 min. The UGT2B15 polymorphism 
D85Y (rs1902023) was genotyped as above but with 900nM primer and 200nM probe 
concentrations and the PCR was extended to 50 cycles. UGT2B4 and UGT2B7 genotyping 
reactions used TaqMan core reagents (cat#4304439), 5ng DNA, 200nM primers, 5mM 
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(UGT2B4) and 4mM (UGT2B7) MgCl2, 50nM (UGT2B4) and 200nM (UGT2B7) probes, 
and 50 PCR cycles. All assays were validated on 30 CEPH family trios purchased from the 
Coriell Cell Repository (CEPH HAPMAPPT01).
Five polymorphisms (UGT1A5 A158G (rs12475068), UGT1A6 S7A (rs6759892), UGT1A9 
-275T>A (rs6714486), UGT2B4 3′UTR (rs1131878) and UGT2B4 5′UTR (rs1966151)) 
were genotyped using the Illumina GoldenGate platform and the Veracode BeadXpress 
Reader (Illumina, Inc. San Diego, CA) as described previously (Kleinstein et al., 2013). Call 
rates for all five genotypes exceeded 98%. The concordance for blinded duplicates was 
100%.
The promoter repeat polymorphism in UGT1A1 (rs34815109) was genotyped using the 
GeneScan assay, as previously described (Thomas et al., 2006). The exon 1 polymorphisms 
in UGT1A3 and UGT1A7 were genotyped using direct sequencing, as described (Thomas et 
al., 2006).
For quality control, all assays were validated using the 30 CEPH family trios prior to 
running study samples. Each assay batch contained negative and positive controls and 5% of 
the total number of samples were re-genotyped to confirm reproducibility. All genotypes 
were also reviewed independently by two technicians. Laboratory staff was blinded to case-
control status for all assays.
Two polymorphisms (rs28898617 and rs6431625), both located in UGT1A3 were not in 
Hardy-Weinberg Equilibrium and thus were excluded from further analyses.
Statistical Analysis
The associations between polymorphisms and the risk of colorectal cancer were assessed 
with conditional logistic regression models estimating odds ratios (OR) and 95% confidence 
intervals (CI) (Horvath and Laird, 1998; Gauderman et al., 1999). All models used kinship 
as the matching variable and adjusted for age and sex. For each polymorphism, the risk of 
colorectal cancer, rectal cancer, and colon cancer (combining proximal and distal) was 
estimated using a co-dominant model unless any cell had fewer than 30 individuals, in 
which case a dominant model was used. A recessive model was not estimated as the sample 
sizes were too small for this analysis. A trend test was performed using the log-additive 
model to investigate dose-dependent associations with the variant allele. Combined analyses 
of all polymorphisms within each gene and haplotype analyses were also conducted. For the 
combined genotype analyses, genotype combinations within each gene were analyzed both 
individually and in a dominant analysis, where those with at least one variant allele in a 
genotype combination were compared with those carrying only the major alleles. For the 
haplotype analyses, haplotype frequencies in cases and controls were inferred with the SAS/
Genetics software module. For haplotypes with fewer than 5 individuals per cell, haplotypes 
were combined in one category (HRare). The analyses were carried out using the 
expectation-maximization algorithm to generate maximum likelihood estimates of haplotype 
frequencies.
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We also investigated polymorphism interactions with NSAID, aspirin or ibuprofen use 
between current users vs. never/former users. In this study population, current NSAID use 
was more strongly inversely associated with colorectal cancer risk than other aspects of 
NSAID use and thus we chose it as the primary variable for interaction analysis. The 
reference groups were comprised of individuals who were homozygous for the wild-type 
allele(s) and never/former users of NSAIDs. Because use of NSAIDs may be associated 
with other known risk factors for colorectal cancer, NSAID interactions were adjusted for 
smoking (continuous pack-years), body mass index (BMI; continuous), and physical activity 
(four-level ordinal variable based on average MET hours) in addition to age (continuous) 
and sex. We assessed the interaction between genotype and the use of both aspirin and 
ibuprofen on a multiplicative scale using the cross-product of NSAID exposure and 
genotype; the likelihood-ratio test was used to determine the statistical significance of the 
interaction.
All tests of statistical significance were two-sided at α=0.05. The false discovery rate (FDR) 
of Benjamini and Hochberg was used to correct for multiple testing (Benjamini and 
Hochberg, 1995; Benjamini et al., 2001). Most of the investigated polymorphisms were 
selected based on functional significance at an in vitro or in silico levels, thus we used the 
FDR at 25%. Analyses were conducted using SAS Version 9.3 for Windows (SAS Institute 
Inc., Cary, NC).
Results
Characteristics of the study population are presented in Table 1. We observed no statistically 
significant differences between cases and unaffected sibling controls by age; regular 
NSAID, ibuprofen, or aspirin use; physical activity; or BMI. Cases were more likely to be 
male (p<0.01). A summary of genotyped polymorphisms and respective minor allele 
frequencies is given in Supplementary Table 1. Allele frequencies were consistent with 
previous studies in Caucasian populations (Bigler et al., 2001; Chan et al., 2005; Dura et al., 
2012).
SNP risk estimates
Out of 18 analyzed polymorphisms, one showed a significant association with colorectal 
cancer risk (Supplementary Table 2). A non-synonymous polymorphism in the UGT2B15 
gene (rs1902023, T>G; UGT2B15*2), which leads to a tyrosine to aspartic acid change at 
position 85, statistically significantly increased the risk of colorectal cancer (OR 1.34; 95% 
CI 1.10-1.63, p-value=0.02) in individuals with the TG genotype (Table 2). The risk of 
colorectal cancer for homozygous carriers of the variant allele was not statistically 
significant (OR 1.27; 95% CI 0.97-1.67). Similarly, in an additive analysis, no significant 
association was observed. No other polymorphisms were statistically significantly 
associated with risk of colorectal cancer.
As previous studies have shown that haplotypes or genotype combinations of UGT 
polymorphisms may have a larger impact on enzyme activity than a single nucleotide 
change, we also investigated haplotypes within each UGT gene and across the UGT1A locus, 
as well as combined genotypes within each genotyped gene for association with colorectal 
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cancer risk (Supplementary Tables 3, 4 and 5). Although none of the haplotypes were 
statistically significantly associated, a three-SNP genotype within UGT1A6 was associated 
with risk of colorectal cancer (Table 3). Individuals who were homozygous for the major 
alleles of the polymorphisms rs2070959 (A>G; Thr181Ala) and rs1105879 (A>C; 
Arg184Ser) and, additionally, homozygous for the rs6759892 (T>G; Ser7Ala) minor G-
allele of the UGT1A6 gene, i.e. the UGT1A6*3 allele (Bock et al., 2005), were at a 3.9-fold 
higher risk of colorectal cancer (OR 3.87; 95% CI 1.04-14.45) than individuals carrying 
only the major alleles of all three polymorphisms (UGT1A6*1). This association was 
noteworthy at the 25% FDR level.
NSAID interactions
Several of the investigated variants showed a significant (p<0.05) interaction with the 
modification of colorectal cancer risk by NSAID use; however, some of these results were 
based on small cell sizes and should be considered tentative.
The UGT1A3 Thr78Thr (rs17868336; A>G) variant showed a statistically significant 
interaction with NSAID use (p-interaction=0.02), increasing the risk of non-NSAID users 
with the homozygous minor G-allele genotype by 50% (OR 1.57; 95% CI 1.06-2.34, Table 
4.a) in comparison to non-users with the major A-allele.
A stratified analysis by tumor site showed a statistically significant interaction between two 
of the UGT1A6 polymorphisms (Ser7Ala and Arg184Ser) and NSAID use for risk of rectal 
cancer (p-interaction=0.03, Table 4.b, and p-interaction=0.02, Table 4.c respectively).
We also investigated whether haplotypes across the UGT1A locus, within any of the 
investigated UGT genes, where several polymorphisms were genotyped (i.e. UGT1A3, 
UGT1A6, UGT1A7, UGT2B4 and CYP2C9) or combined genotypes within any of the 
investigated genes interacted with NSAID use, or specifically, ibuprofen or aspirin in 
colorectal cancer predisposition. No interactions were observed with overall NSAID use; 
however, the use of ibuprofen was associated with a higher risk of colorectal cancer in 
individuals who were homozygous for the major alleles of all three investigated UGT2B4 
polymorphisms (rs1966151, A>G, 5′UTR; rs13119049, A>T, Asp458Glu; rs1131878, A>G, 
3′UTR; OR 2.31; 95% CI 1.07-4.97), whereas ibuprofen users who carried at least one 
variant allele at any of the three loci tended to be at lower risk (OR 0.73; 95% CI 0.48-1.12) 
of colorectal cancer than non-users with only major alleles (p-interaction=0.0018, Table 5). 
When we accounted for multiple testing based on FDR, this association was noteworthy at 
the 25% FDR level.
Additionally, the coding variant Tyr85Asp in the UGT2B15 (UGT2B15*2) gene showed a 
statistically significant interaction with aspirin use (p-interaction=0.01). Individuals who 
were homozygous for the minor G-allele and used aspirin were at higher risk of colorectal 
cancer (OR 1.71; 95% CI 1.07-2.73), than non-users who carried only the major T-allele 
(Figure 1 and Table 6). This association was noteworthy at the 25% FDR level.
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Colorectal cancer is a heterogeneous disease and targeted prevention strategies are required 
to reduce the public health burden of the disease (Colussi et al., 2013). In light of extensive 
data on the preventive effects of aspirin and other NSAIDs on risk of cancer, there is 
growing interest in determining whether genetic variation in NSAID-metabolizing enzymes 
can be used to predict the protective effect of NSAIDs on cancer development and on 
complications such as gastrointestinal bleedings (Derry and Loke, 2000; Ulrich et al., 2006; 
Cross et al., 2008; Cuzick et al., 2009; Chia et al., 2012; Kraus et al., 2013; Rothwell at al., 
2010; 2012a; 2012b; 2013). Since metabolizing enzymes can modify, conjugate, and/or 
excrete endobiotic or xenobiotic compounds, including the detoxification of carcinogens and 
metabolism of chemopreventive or chemotherapeutic compounds, genetic variability in 
these enzymes may thus alter the toxicity or efficacy of xenobiotics and consequently alter 
cancer susceptibility.
In this large population-based study of sibling pairs in the CCFR, we investigated whether 
polymorphisms within genes of phase I (CYP2C9) and phase II (UGT) drug-metabolizing 
enzymes were associated with or modified the protective effect of NSAIDs on colorectal 
cancer risk. In addition to previously investigated polymorphisms, we targeted several 
previously unstudied polymorphisms in UGT genes in this study.
Variants in four genes (UGT1A3, UGT1A6, UGT2B4 and UGT2B15) were statistically 
significantly associated with colorectal or rectal cancer risk either in individual analysis, 
combined genotype analysis, or in combination with NSAID use. The interaction between 
the UGT2B15 Tyr85Asp polymorphism and aspirin use (which was also associated with risk 
overall) as well as between a three-SNP genotype in UGT2B4 and ibuprofen use were 
noteworthy at the 25% FDR level.
This study is the first to report the association of the UGT1A6*3 polymorphism, a three-SNP 
genotype (Ala7, Thr181, Arg184), with increased colorectal cancer risk; previous studies 
had focused on a two-SNP genotype within UGT1A6 (Thr181Ala, Arg184Ser, i.e. 
UGT1A6*8 also referred to as UGT1A6*2 in some studies) (Bigler et al., 2001; Chan et al., 
2005; McGreavey et al., 2005; Samowitz et al., 2006). Nonetheless, these results require 
further validation, as the association was based on few individuals and thus stratification by 
tumor location was not possible. In vitro investigations of the UGT1A6*3 variant enzyme 
showed no significant change of the enzymatic activity compared to the wild type enzyme 
UGT1A6*1 (Krishnaswamy et al., 2005b). However, the family of UGT1A genes represents 
a complex locus consisting of four common exons and at least 13 variable exons with many 
shared sequences and polymorphisms among the UGT1A genes (Mackenzie et al., 2005). 
The complexity of the UGT1A region is further increased by its LD structure; many SNPs 
are linked to each other, thus making it difficult to identify the causal variation and the 
related gene or enzyme product. The Ser7Ala polymorphism is in complete LD with other 
polymorphisms in the UGT1A locus, including three polymorphisms located in the 5′UTR of 
the gene, associated with 50% decreased gene expression of UGT1A6, but not with lower 
protein levels or reduced enzyme activity (Krishnaswamy et al., 2005a; Thomas et al., 
2006), thus the functional consequence of these polymorphisms remains to be elucidated. 
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Previous studies have shown that the UGT1A6*8 allele (two-SNP genotype: Ala181 and 
Ser184) modified the protective effect of aspirin on colon or colorectal adenoma; however, 
no study has shown similar effects on the risk of colon carcinoma (Bigler et al., 2001; Chan 
et al., 2005; McGreavey et al., 2005; Samowitz et al., 2006; Thompson et al., 2009), 
concordant with our observations. It has been proposed earlier that the protective effect of 
NSAIDs may occur earlier during carcinogenesis and may thus be relevant for adenoma 
prevention rather than for prevention of carcinomas (McGreavey et al., 2005). However, 
recent meta-analyses (Rothwell et al., 2012a; 2012b) strongly suggest that the preventive 
effect of NSAIDs exists across all stages of colorectal neoplasia. Nevertheless, further 
investigation regarding dose, treatment duration and long-term benefit of NSAID use are 
required to optimize its use in cancer prevention (Cuzick et al., 2009; Potter, 2012).
In the present study we observed an association of a UGT2B15 variant with increased risk of 
colorectal cancer, which also interacted with aspirin use in colorectal cancer predisposition, 
as well as novel interactions between UGT2B4 polymorphisms and ibuprofen. Both the 
UGT2B4 and the UGT2B15 enzymes are primarily involved in the metabolism of sex 
hormones. Polymorphisms within these genes have been associated with increased breast 
and prostate cancer risk, respectively (MacLeod et al., 2000; Park et al., 2004; Low et al., 
2010; Grant et al., 2013). While UGT2B4 has been shown to metabolize NSAIDs at quite 
high rates, UGT2B15-mediated glucuronidation was observed only at low rates (Kuehl et 
al., 2005; 2006). In vitro studies of the UGT2B15 variant enzyme displayed similar substrate 
specificity between the Tyr85 and the Asp85 enzymes; however, the Asp85 variant enzyme 
had a faster turn-around time (i.e. higher Vmax) (Levesque et al., 1997). This may lead to a 
reduced internal dose of the active drug compound accompanied by reduction of its 
preventive effect. The previously reported associations with cancer risk are probably due to 
changed sex steroid metabolism resulting in altered tissue exposure to hormones capable of 
stimulating cell proliferation (Yong et al., 2011). However, the strong interaction between 
the UGT2B15 polymorphism and aspirin use in relation to colorectal cancer risk, which 
remained significant after accounting for multiple testing, suggests a meaningful role of the 
enzyme in NSAID metabolism. Nevertheless, it seems that larger structural genetic variation 
such as copy number variations (CNV) have a stronger impact on cancer risk as previously 
reported in recent study. It was shown that a large CNV that leads to the deletion of the 
UGT2B17 gene, significantly decreased the risk of rectal cancer (Angstadt et al., 2013), but 
not colon cancer.
Concordantly with a recent meta-analysis which covered 13 studies, we did not observe an 
association between any of the CYP2C9 polymorphisms and risk of colorectal cancer (Liang 
et al., 2012). While an interaction of the polymorphisms with NSAID use on colorectal 
cancer risk was reported previously, in this study no interaction was observed (Bigler et al., 
2001; Samowitz et al., 2006).
There are several strengths to this study. The case–unaffected sibling control design helps 
avoid false positives that can result from population stratification and increases the power to 
detect gene–NSAID interactions. The relatively large overall sample size in this study made 
it possible to examine combined genotypes, as well as interaction analysis for NSAID use. 
There are several potential limitations to our study. Current NSAID use was only modestly 
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associated with reduced CRC risk in our study population, which may limit the power for 
detection of gene-NSAID interaction. The family-based study design likely reduced the 
power of the main effect analyses. Furthermore, despite the large sample size, interaction 
analysis with combined genotypes or specific NSAIDs resulted in small cell sizes, reducing 
the precision of estimates and the power. When we tested the interactions for multiple 
comparisons at the 25% FDR level, only the interaction of the UGT2B4 combined genotype 
with NSAID use and the UGT2B15*2 with aspirin use were noteworthy. On the other hand, 
we investigated specific hypotheses with respect to putative gene-NSAID interactions and 
functional polymorphisms; in this setting adjustment for multiple comparisons is less 
critical. Finally, our study was based on the investigations of SNPs, thus we did not cover 
larger structural variants in UGT genes, which may have a stronger impact on colorectal 
cancer risk.
In summary, our results suggest that variation in four genes (UGT1A3, UGT1A6, UGT2B4 
and UGT2B15) modifies the risk of colorectal cancer either independent or in conjunction 
with NSAID use. Our results underscore the importance of pharmacogenetics as a tool to 
identify individuals who may benefit from NSAIDs as chemopreventives. In addition, our 
study results suggest that it appears to be more important to consider combinations of 
genotypes rather than individual polymorphisms to identify the interaction between genetic 
variability and the protective effect of NSAID use on colorectal cancer development, 
particularly for UGT families.
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Table 1
Selected characteristics of population-based Colon Cancer Family Registry kinships 





Age (y), mean (SD) 53.5±10.8 54.0±11.7
Gender
 Female 774 (48.9) 1390 (55.3)
 Male 810 (51.1) 1126 (44.7)
Family History of Cancerb
 Yes 506 (32.5) 771 (31.1)
 No 1051 (67.5) 1708 (68.9)
Center
 Ontario 296 (18.7) 491 (19.5)
 USC (University of Southern California) 319 (20.1) 444 (17.7)
 Australia 317 (20.0) 554 (22.0)
 Hawaii 6 (0.4) 7 (0.3)
 Mayo Foundation 266 (16.8) 502 (20.0)
 Seattle 380 (24.0) 518 (20.6)
Tumor site
 Proximal 526 (33.2) -
 Distal 460 (29.0) -
 Rectal 523 (33.0) -
Regular Aspirin usec
No 1320 (84.1) 2080 (84.1)
Yes 250 (15.9) 394 (15.9)
Regular Ibuprofen usec
No 1444 (92.5) 2255 (90.9)
Yes 117 (7.5) 226 (9.1)
Regular NSAID usec
No 1234 (78.2) 1916 (76.9)
Yes 343 (21.8) 577 (23.1)
Physical activity
Inactive 375 (23.7) 585 (23.3)
Less active 424 (26.8) 679 (27.0)
Active 374 (23.6) 564 (22.4)
Very active 338 (21.3) 548 (21.8)
BMI [kg/m2]±SD 27.4 ± 6.0 26.8 ± 5.5
Cigarette smoking (pack-years)±SD 12.9 ±19.5 11.7 ± 19.3
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a




Regular Aspirin, Ibuprofen and NSAID use defined as regular use of least two pills per week for at least one month.
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